Denali Therapeutics Inc.
Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151…
Biotechnology
US, South San Francisco [HQ]
DNLI/Financial Reporting
Income Statements
Profit & Loss · 9 Statements · From 2023 to 2015Configuration
In Million USD. Margins, Growth Rates In %
| Metric | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - - | - - | - - | 129.00 | 26.00 | 335.00 | 48.00 | 108.00 | 330.00 | |
|
EPS
|
-5.58 | -13.49 | -5.89 | -0.39 | -2.07 | 0.65 | -2.39 | -2.60 | -1.06 | |
| Diluted in mil. | -5.58 | -13.49 | -5.89 | -0.39 | -2.07 | 0.63 | -2.39 | -2.60 | -1.06 | |
|
Profit
|
- - | - - | - - | 129.00 | -166.00 | 123.00 | 43.00 | 101.00 | 313.00 | |
| Gross Margin | - - | - - | - - | 100.00 | -624.87 | 36.66 | 88.47 | 93.52 | 94.94 | |
| Pre Tax | -16.00 | -86.00 | -88.00 | -36.00 | -197.00 | 71.00 | -291.00 | -325.00 | -145.00 | |
| Profit Margin | - - | - - | - - | -28.06 | -742.05 | 21.44 | -598.34 | -300.54 | -43.93 | |
| ETR | - - | - - | 3.49 | -27.96 | 0.18 | 1.14 | 0.20 | -0.01 | -0.02 | |
| Net | -16.00 | -86.00 | -88.00 | -36.00 | -197.00 | 71.00 | -290.00 | -325.00 | -145.00 | |
| Profit Margin | - - | - - | - - | -28.06 | -740.74 | 21.19 | -597.15 | -300.56 | -43.94 | |
| EBITDA | -16.00 | -85.00 | -90.00 | -46.00 | -213.00 | 62.00 | -295.00 | -330.00 | -179.00 | |
| EBITDA Margin | - - | - - | - - | -35.90 | -799.10 | 18.69 | -607.78 | -304.58 | -54.45 | |
| Operating Income | -16.00 | -87.00 | -90.00 | -46.00 | -213.00 | 62.00 | -295.00 | -340.00 | -196.00 | |
| Operating Margin | - - | - - | - - | -35.90 | -799.10 | 18.69 | -607.78 | -314.16 | -59.51 | |
| Interest Income | - - | - - | 1.00 | 10.00 | 15.00 | 9.00 | 4.00 | 14.00 | 51.00 | |
| Loss | -16.00 | -87.00 | -90.00 | -175.00 | -239.00 | -272.00 | -344.00 | -449.00 | -527.00 | |
| Cost of Revenue | - - | - - | - - | - - | -193.00 | -212.00 | -5.00 | -7.00 | -16.00 | |
|
Operating Expenses
|
-16.00 | -87.00 | -90.00 | -175.00 | -239.00 | -272.00 | -344.00 | -449.00 | -510.00 | |
| R&D | -11.00 | -75.00 | -74.00 | -143.00 | -193.00 | -212.00 | -265.00 | -358.00 | -423.00 | |
| G&A | -5.00 | -11.00 | -15.00 | -32.00 | -46.00 | -60.00 | -79.00 | -90.00 | -103.00 | |
| SG&A | -5.00 | -11.00 | -15.00 | -32.00 | -46.00 | -60.00 | -79.00 | -90.00 | -86.00 | |
| S&M | - - | - - | - - | - - | - - | - - | - - | - - | -16.00 | |
| Depreciation and Amortization | - - | -1.00 | -3.00 | -7.00 | -7.00 | -8.00 | -8.00 | -10.00 | -16.00 | |
| Interest Expenses | - - | - - | -1.00 | - - | -15.00 | - - | - - | -14.00 | - - | |
| Other Expenses | - - | - - | -1.00 | -10.00 | -15.00 | -9.00 | -4.00 | -14.00 | -51.00 | |
|
WA Shares Outstanding
|
3.00 | 6.00 | 14.00 | 92.00 | 95.00 | 108.00 | 121.00 | 125.00 | 137.00 | |
| Diluted | 3.00 | 6.00 | 14.00 | 92.00 | 95.00 | 112.00 | 121.00 | 125.00 | 137.00 |